Current Trends of Drug Resistance Patterns of Acinetobacter baumannii Infection in Blood Transfusion-dependent Thalassemia Patients
Abstract
Objective: The current study aimed to judge the present trends of drug resistance patterns of Acinetobacter baumannii infection in bloodstream transfusion-dependent thalassemia patients.
Study design: This research would be a mix sectional study, conducted in the Liaquat College of Health and medical Sciences, Jamshoro/Hyderabad, Sindh, Pakistan from October 2014 to The month of january 2016.
Subjects and techniques: Of 921 bloodstream samples, A. baumannii strains were isolated from 100 bloodstream samples. Bloodstream samples were processed for that isolation, identification, and medicines sensitivity as reported by the Clinical and Laboratory Standards Institute. A. baumannii strains were recognized by microbiological methods and Gram’s staining. API 20 E package (Biomeriuex, USA) seemed to be employed for identification. Data were examined on Statisti × 8.1 (USA).
Results: Mean ± standard deviation age was 11.5 ± 2.8 years. Nearly 70% were male and 30% were female (P = .0001). Of 921 bloodstream transfusion-dependent thalassemia patients, 100 (10.8%) patients demonstrated development of A. baumannii. Drug resistance was observed from the ceftazidime, cefixime, cefepime, imipenem, meropenem, amikacin, minocycline, tigecycline, and tazocin aside from the colistin.
Conclusion: The current study reports drug-resistant A. baumannii in bloodstream transfusion-dependent thalassemia patients. National multicenter research is suggested to estimate how big the Tigecycline issue.